These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33193085)

  • 1. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.
    Drozd V; Schneider R; Platonova T; Panasiuk G; Leonova T; Oculevich N; Shimanskaja I; Vershenya I; Dedovich T; Mitjukova T; Grelle I; Biko J; Reiners C
    Front Endocrinol (Lausanne); 2020; 11():567385. PubMed ID: 33193085
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
    Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
    Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
    Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
    Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
    van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
    Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
    [No Abstract]   [Full Text] [Related]  

  • 7. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis.
    Piek MW; Postma EL; van Leeuwaarde R; de Boer JP; Bos AME; Lok C; Stokkel M; Filipe MD; van der Ploeg IMC
    Thyroid; 2021 Apr; 31(4):658-668. PubMed ID: 33012254
    [No Abstract]   [Full Text] [Related]  

  • 8. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
    Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
    Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
    Chow SM; Yau S; Lee SH; Leung WM; Law SC
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
    Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
    Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis.
    Nappi C; Klain M; Cantoni V; Green R; Piscopo L; Volpe F; Maurea S; Petretta M; Cuocolo A
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1630-1639. PubMed ID: 34820683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
    J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
    Wu W; Li S; Xu K; Meng Z
    Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
    Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
    J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid cancer in infants and adolescents after Chernobyl.
    Reiners C; Demidchik YE; Drozd VM; Biko J
    Minerva Endocrinol; 2008 Dec; 33(4):381-95. PubMed ID: 18923372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
    Molenaar RJ; Sidana S; Radivoyevitch T; Advani AS; Gerds AT; Carraway HE; Angelini D; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
    J Clin Oncol; 2018 Jun; 36(18):1831-1839. PubMed ID: 29252123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
    Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
    Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.